GlassScriptPhysician profile
Hadley C King
NPI 1780790238
$2,549.09
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $301 · 2021: $307 · 2022: $512 · 2023: $178 · 2024: $54.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $979.61 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $301.64 | 2021-2023 | Jublia |
| Merz North America, INC. | $283.57 | 2019-2024 | |
| Allergan, INC. | $229.62 | 2019-2021 | |
| Genzyme Corporation | $118.01 | 2019 | |
| Sun Pharmaceutical Industries INC. | $95.21 | 2021-2023 | Absorica Ld, Winlevi |
| Dermavant Sciences, INC. | $95.15 | 2023 | Vtama |
| Epi Health, LLC | $77.18 | 2020-2022 | |
| Lilly USA, LLC | $70.90 | 2020-2021 | |
| Journey Medical Corporation | $63.35 | 2020-2022 | |
| Abbvie INC. | $57.80 | 2020-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $43.80 | 2019 | |
| Amgen INC. | $27.25 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.58 | 2020 | |
| Ucb, INC. | $23.28 | 2023 | Cimzia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $21.09 | 2021 | |
| Mayne Pharma Commercial LLC | $20.93 | 2021 | |
| Dermira, INC. | $16.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadley King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.